Posted on January 27th, 2010 by
Compared with a placebo, treatment with the oral, targeted drug Votrient® (pazopanib) delays progression of advanced kidney cancer. The results of this Phase III clinical trial were published in the Journal of Clinical Oncology.
The kidneys are filled with tiny tubules that clean and filter the blood; this process removes waste and makes urine. Renal cell cancer (RCC) is a malignancy involving these tubules of the kidney. It is the most common type of kidney cancer.
Votrient is an oral medication that targets certain biological pathways involved in cancer growth and spread.
The efficacy of Votrient in locally advanced or metastatic RCC was evaluated in a Phase III clinical trial. The study enrolled 233 previously untreated patients and 202 patients who had previously been treated with either interferon or interleukin. Patients were assigned to receive either Votrient or a placebo.
The results of this study suggest that compared with placebo, Votrient delays progression of advanced kidney cancer. Additional studies will compare Votrient to other targeted therapies for kidney cancer.
Reference: Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology [early online publication]. January 25, 2010.
You must be logged-in to the site to post a comment.